1 / 40

Transplantation Science

Transplantation Science. Lars Wramner MD, Ph.D. Transplantation. Organs: Kidney, liver, heart, lung, pancreas Tissues: Cornea, skin, bone, heart valves Blood: Erythrocytes, trombocytes, plasma Bone marrow:. Transplantation. Autotransplantation Within one individual

elam
Télécharger la présentation

Transplantation Science

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Transplantation Science Lars Wramner MD, Ph.D.

  2. Transplantation • Organs: • Kidney, liver, heart, lung, pancreas • Tissues: • Cornea, skin, bone, heart valves • Blood: • Erythrocytes, trombocytes, plasma • Bone marrow:

  3. Transplantation • Autotransplantation • Within one individual • Isotransplantation • Between genetically identical individuals • Allotransplantation • Between individuals from the same species • Xenotransplantation • Between different species

  4. Transplantation antigens • Antigen: A molecule recognised as foreign • Blood group antigens • The ABO-system • MHC: The Major Histocompatibility Complex • Humans: HLA, Human Leukocyte Antigens • Mouse: H2. Rats: RT1 • Enormous heterogeneity • Others

  5. Specific -Nonspecific • Non -specific inflammatory mechanisms: • Macrophages, dendritic cells. • NK cells • Granulocytes • Complement • Antigen-specific immune response: • T-lymphocytes: TH, TC. • B-lymphocytes: Immunoglobulin, IG.

  6. MHC • Location: • On the surface of nucleated cells. • Function: • Antigen presentation. A foreign molecule + the MHC-molecule = altered self => antigen. • Transplantation. A foreign MHC-molecule = altered self => transplantation antigen. • Inflammation: • Upregulated

  7. Immune activation • Antigen presentation. • Cell-to-cell adhesion. • Signalling molecules. • Cytokine gene polymorphism. • Cell activation. • Effector mechanisms.

  8. Antigen presentation • Antigen presenting cells, APC. • Macrophages, dendritic cells • Antigen presentation • Direct: Donor-APC with donor-MHC. • Indirect: Recipient-APC with donor-MHC.

  9. Cell-to-cell adhesion • Close and stable adhesion: • Antigen presentation. • Facilitate signalling. • Adhesion molecules: • IgSF (ICAM, VCAM, LFA-3) • Integrins: 1,2,3, LFA-1 • Selectins: E,L,P-selectins

  10. Signalling molecules • Co-stimulation • Cytokines: • Interleukins, IL • Interferons • TNF • TGF- • Others • Regulation of the immune response

  11. Cytokine gene polymorphism • SNP, single nucleotide polymorphism. • Promoter region. • Detected by PCR-technique. • Inter-individual variation in cytokine- production or receptor activity. • Different clinical outcome.

  12. Cell activation • Step 1: Antigen - cytokine • Ca-dependent pathway • Ca-independent pathway • Step 2: Cytokine - cell proliferation cycle • RAFT 1 • G1 -> S phase • Purine synthesis • DeNovo pathway • 7-10 days.

  13. Effector mechanisms • TC (CD-8): Killer cells, cytotoxic cells. • TH (CD-4): Helper cells, promote inflammation. • B-lymphocytes: Antibody production,

  14. Acute rejection • Cellular infiltration • Cytokine production • Upregulation of MHC • Tissue destruction • Cytotoxic T cells • Complement activation by antibodies • Thrombosis • Fibrosis

  15. Clinical signs of acute rejection • Kidney: • Creatinine elevation • Lack of creatinine decline • Liver: • Abnormal liver values. • Thoracic organs • Protocol biopsies.

  16. Clinical classification of rejections:- Chronological • Hyperacute: • Preformed antibodies. • Within minutes-hours. • Acute: • Mainly cellular • Within weeks, < 3 months. • Chronic: • After years, slowly progressing.

  17. Clinical classification of rejections:- Sensitive to treatment • Steroid treatment: • Sensitive. • Resistant. Need for antibody treatment. • Outcome • Return to baseline level • Stable at an elevated level • Progressive

  18. Chronic rejection • Inflammation • Arteriosclerosis • Intimal thickening • Fibrosis • Organ specific destruction's • Glomerular sclerosis and tubular atrophy • Vanishing bile ducts and cellular ballooning • Brochiolitis obliterans

  19. Tolerance • Absence of activation: • Self tolerance! • Foetal tolerance! • Tumour tolerance? • Transplantation tolerance? • Mechanisms: • Anergy • Clonal deletion • Suppresser cells

  20. Clinical results, kidney • Acute rejection: • 50 %. Nearly always reversible. • Increased risk of chronic rejection. • 1-year results: • 95 % patient survival. • 85-90 % graft survival. • Few infections, normal life. • Long term: • 50 % graft survival, appr 15 years.

  21. TNF-gene polymorphism and graft survival

  22. Val av främmande organ • Blodgruppstillhörighet. • Undantag, A2 -> 0 • Transplantationsantigen • Enäggstvilling • HLA-identiska syskon • Övriga utan främmande HLA-antigen • Med påvisbara främmande antigen, > 90 %

  23. Immunosuppression

  24. Historik • 60-talet: • Steroider (Prednisolon) • Azathiprin (Imurel) • 80-talet: • Calcineurinhämning I: Cyclosporin (Sandimmun) • Lymfocytantikroppar: Polyklonalt (ATG), monoklonalt (OKT-3) • 90-talet: • Calcineurinhämning II: FK506 (Prograf) • Purinesynteshämning: MMF (Cellcept) • TOR-hämning: Rapamycin (Rapamune), Everolimus (?) • IL-2 receptor hämning: Monoklonal a-k (Simulect, Zenapax)

  25. Steroider • Verkan: Hämmar arachidonsyre kaskaden, antigenpresentation, cytokinproduction, adhesionsmolekyler och MHC-II och cellinteraktioner. • Biverkan: Hypertoni, blodsockerhöjning, osteoporos, acne, hudatrofi, hämmad sårläkning, ulcus och muskelatrofi. • Användning: • Profylax: Snabbt sjunkande, lågdos. • Rejektion: Högdos några dar.

  26. Cytokinhämning I • Verkan:Synteshämning genom calcineurinblockad. • Cyclosporin, CyA: Sandimmun Neoral • Tacrolimus, FK506: Prograf • Biverkan: • Njurtoxicitet, hypertoni, hårväxt (CyA), tremor, gingiva hyperplasi, atheroscleros?

  27. Calcineurinhämning

  28. Cytokinhämning II • Verkan: Il-2 receptorblockad. Monoklonal antikropp, Simulect och Zenapax. • Biverkan: Immunhämning !? • Ges som injektion 2-5 gånger. • Immunhämning i 2-5 månader.

  29. Cytokinhämning III • Verkan: Hämmar effekten av receptoraktivering genom blockad av TOR. • Rapamycin: Rapamune • Everolimus: ? • Biverkan: Hyperlipidemi, lätt benmärgshämning, ledbesvär, slemhinnesår, pneumonit. • Ej nephrotoxiskt. • Hämmar cellproliferation: Tumörer, blodkärlsendotel, ospecifik inflammation !? • Leflunomid ??

  30. TOR-hämning

  31. Hämning av celldelning • Verkan: Hämmar celldelning, främst lymfocyter, genom purinsyntes hämning. • Azathioprine (Imurel) • MMF (Cellcept). Mer selektivt för lymfocyter. • Biverkan: Buksmärtor och diarré, pancytopeni och slemhinnebesvär. • Mizoribine ? • Brequinarsodium ?

  32. Purinsynteshämning

  33. Antilymfocytantikroppar • Verkan: Något oklar. Förmodligen celldöd, lys, och redistribution. Ger långvarig lymfopeni i perifert blod. • Biverkan: • Kraftiga akut influensaliknande besvär. • Ledvärk. • Ökad infektionsrisk. • Risk för lymfom, senare. • Användning: • Induktion. • Avstötning. • Preparat: • Polyklonalt: ATG • Monoklonalt: OKT-3

  34. Klinisk immunhämning I. • Inga mätmetoder av immunologisk hämning. • Läkemedelskoncentration. • Leukocytnivåer. • Allmänna doseringar: • Vetenskap, kliniska studier. • Beprövad erfarenhet. • Minimera biverkningar. • Kostnadseffektivt

  35. Klinisk immunhämning II • Kombinationsterapi: • Trippel-, dubbel- eller monoterapi. • Successiv dosreduktion. • Profylaktisk terapi. • Induktion, högdos. • Underhåll, lågdos. • Avstötningsterapi: • Högdos steroider, 3-5 dar. • Antilymfocytantikroppar

More Related